Isatuximab-irfc (Sarclisa®) in 1q21 Gain orAmplifications in Relapsed/Refractory Multiple Myeloma

This PQI in Action is a follow up to the Isatuimab-ifc-Regimens in 1q21 Gain or Amplications in Relapsed/ Refractory Multiple Myeloma PQI and explores how the medically integrated teams at Texas Oncology, Florida Cancer Specialists & Research Institute (FCS), and University Hospitals Cleveland Medical Center, Seidman Cancer Center collaborate and utilize the information found in the PQI as part of their daily practice. This PQI in Action focuses on the use of isatuximab in combination with carfilzomib and dexamethasone or with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma with 1q21 gain or amplification.